Inna Vernovsky, MD
Critical Care Medicine · Newton, MANPI 1871569681
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 70.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $514 and has fallen 97.3% since, to $14 in 2024.
Across 53 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$698
- AstraZeneca$227
- Sunovion Pharmaceuticals Inc.$44
- Circassia Inc.$17
What the payments were for
- Food & beverage$985100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 45 | $698 |
| AstraZeneca | 4 | $227 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Circassia Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- TEZSPIRE$114
- NUCALA$113
How this compares
$985 in reported general payments places this provider in the 70th percentile of 158 critical care medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 329 | $305,690 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 151 | $124,101 |
| Breo ElliptaFluticasone/Vilanterol | 109 | $69,000 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $30,697 |
| Incruse ElliptaUmeclidinium Bromide | 52 | $30,621 |
| Advair HfaFluticasone Propion/Salmeterol | 51 | $28,584 |
| Arnuity ElliptaFluticasone Furoate | 51 | $25,319 |
| Wixela InhubFluticasone Propion/Salmeterol | 120 | $18,025 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $12,225 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $11,334 |
| Pulmicort FlexhalerBudesonide | 24 | $9,429 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 257 | $8,928 |
| Spiriva RespimatTiotropium Bromide | 11 | $8,851 |
| Qvar RedihalerBeclomethasone Dipropionate | 21 | $8,044 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $7,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $698 | $461,327593 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $227 | $145,755213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 158 critical care medicine providers in Massachusetts.
Other critical care medicine in Newton
- Richard ChannickBoston$638K
- Ioana PrestonBurlington$544K
- Mark TidswellSpringfield$135K
- Benjamin MedoffBoston$98K
- Jerome CrowleyBoston$38K
- William McGeeSpringfield$32K
- Diana Espinoza BarreraBoston$17K
- Raghu SeethalaWeymouth$14K
- Catherine FioreBoston$13K
- Ilana KrummBoston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.